Route of Adenovirus Type 5-Vectored Influenza Vaccination Shapes Systemic and Mucosal Immunity in a Maternal-Neonatal Pig Model

This study demonstrates that intranasal and intramuscular administration of an adenovirus type 5-vectored influenza vaccine to pregnant pigs effectively induces maternal immunity that is passively transferred to neonates, with the intranasal route showing superior efficacy in generating neutralizing antibodies.

The Gist

Imagine a newborn baby as a tiny, unarmored knight. They are born into a world full of invisible dragons (viruses like the flu), but they haven't learned how to fight yet. Their only shield comes from their mother, who passes down "magic shields" (antibodies) through the placenta and, more importantly, through breast milk.

However, there's a problem: standard flu shots given to pregnant women are like sending a letter to the mother's bloodstream. It works well to build a shield in her blood, but it doesn't always get the "magic shields" into her milk in high enough numbers to protect the baby once they are born.

The Mission
Scientists wanted to find a better way to arm these mothers so they could pass down stronger protection to their babies. They tested a new type of vaccine (a "Trojan Horse" made from a harmless virus called Adenovirus) that carries instructions to build a shield against the flu.

They asked a simple question: How do you deliver this vaccine to get the best results?

1. The Shot (IM): The traditional way, injecting it into the muscle.
2. The Sniff (IN): Spraying it up the nose to target the respiratory system directly.
3. The Swallow (Oral): Giving it as a pill to be digested.

To test this, they didn't use humans (who are too complex and risky for early trials); they used pigs. Pigs are the perfect "practice dummies" because their immune systems, anatomy, and the way they pass milk to their babies are very similar to humans.

The Experiment
The scientists vaccinated pregnant sows (mothers) using one of the three methods. A few weeks later, the piglets were born. The researchers then checked:

• How many "shields" (antibodies) were in the mother's blood?
• How many were in her milk?
• How many did the baby piglets have in their blood?
• Were the shields strong enough to actually stop the flu virus?

The Results: A Tale of Three Routes

• The Swallow (Oral Route): This was the underperformer. Imagine trying to send a letter by throwing it into a river; most of it gets washed away. The pill didn't work well. The mothers' bodies didn't absorb the vaccine instructions properly, so they didn't make many shields, and the babies got almost no protection.
• The Shot (IM Route): This was the reliable workhorse. It worked very well. The mothers built a huge army of shields in their blood, and a good amount made it into the milk. The babies had high levels of protection.
• The Sniff (IN Route): This was the superstar. It did everything the shot did, but with a special twist. Not only did the mothers make strong shields, but the shields they passed to the babies were smarter and stronger.

The "Magic" Difference
Here is the most fascinating part: Even though the babies from the "Shot" group had more shields (higher numbers), the babies from the "Sniff" group had shields that were better at fighting.

Think of it like this:

• The Shot gave the babies a large pile of generic bricks (shields). They could build a wall, but the bricks were a bit weak.
• The Sniff gave the babies fewer bricks, but they were made of reinforced steel. When the flu virus tried to attack, these steel shields blocked it much more effectively.

The "Sniff" route seemed to train the mother's immune system to create high-quality, "special forces" antibodies that are better at neutralizing the virus, even if the total number wasn't the highest.

The Takeaway
This study suggests that for protecting babies who are too young to get vaccinated themselves, sniffing a vaccine (intranasal) might be a better strategy than getting a shot.

It's like realizing that to protect a castle, you don't just need more guards; you need guards who know exactly where the enemy is coming from. By spraying the vaccine up the nose, the mother's body learns to fight the flu exactly where it enters the body (the nose and lungs), creating a specialized defense that gets passed down to the baby in the milk.

In short: While the traditional shot is good, a nasal spray vaccine might be the "secret weapon" needed to give newborns the best possible head start against the flu.

Technical Summary

1. Problem Statement

• Vulnerable Populations: Pregnant women and infants (particularly those under six months) are at high risk for severe influenza complications.
• Current Limitations:
  • No influenza vaccines are approved for infants <6 months.
  • Current maternal vaccination strategies (using Inactivated Influenza Vaccine, IIV) rely on transplacental IgG transfer but fail to stimulate robust mucosal immunity (IgA) in breast milk.
  • IIV does not directly stimulate the mucosal immune system, limiting the trafficking of IgA+ antibody-secreting cells to the mammary gland.
• Objective: To identify a vaccination route that simultaneously induces strong systemic (IgG) and mucosal (IgA) immunity in pregnant/lactating dams to maximize passive antibody transfer to neonates.

2. Methodology

• Animal Model: A maternal-neonatal pig model was used due to its anatomical, genetic, and immunological similarity to humans. Crucially, pigs have an epitheliochorial placenta (no transplacental antibody transfer), meaning piglets rely entirely on colostrum and milk for maternal antibodies, making them an ideal model for studying milk-borne immunity.
• Vaccine Platform: A replication-defective human Adenovirus 5 (huAd5) vector expressing the Hemagglutinin (HA) protein of Influenza A/California/2009 (H1N1), adjuvanted with a TLR3 agonist (VXA-A1.1).
• Experimental Design:
  • Subjects: 16 influenza-naïve pregnant gilts divided into four groups: Oral, Intranasal (IN), Intramuscular (IM), and Control.
  • Regimen: Prime dose administered 3 weeks prepartum; Boost dose administered 1 week postpartum.
  • Sampling: Longitudinal collection of serum, colostrum, milk, nasal swabs, and oral fluids from dams. Piglet serum collected at 2–3 weeks and 5 weeks of age.
  • Endpoints:
    • Humoral: HA-specific IgG/IgA levels (ELISA), Neutralizing Antibody titers (Virus Neutralization Assay), and Hemagglutination Inhibition (HI) titers.
    • Cellular: IFNγ-producing cells via ELISpot in blood, spleen, and lymph nodes.
    • Histopathology: Immunohistochemistry (CD3/CD20) for lymphocyte infiltration in lung and mammary glands.

3. Key Contributions

• Route Comparison: This is the first study to directly compare oral, intranasal, and intramuscular routes of an Ad5-vectored influenza vaccine in a maternal-neonatal system.
• Functional Antibody Quality: The study moves beyond antibody quantity to assess functional quality (neutralization capacity) and how the delivery route influences the "quality" of the passive immunity transferred to offspring.
• Mucosal vs. Systemic Dynamics: It elucidates the compartmentalization of immune responses, showing how different routes drive T-cell trafficking to specific tissues (blood vs. spleen vs. mucosa).

4. Key Results

• Systemic Antibody Responses (Dams):
  • IN and IM routes elicited robust serum HA-specific IgG responses. The IN group showed significantly higher IgG levels than controls at 1 and 4 weeks post-boost. The IM group showed elevated levels but had high variance due to a low-responder animal.
  • Oral route failed to induce significant serum IgG or IgA responses, likely due to limited Coxsackie and Adenovirus Receptor (CAR) expression in the porcine intestinal epithelium.
• Mucosal Antibody Responses (Colostrum/Milk):
  • Colostrum: Both IN and IM groups showed significantly elevated HA-specific IgG compared to controls.
  • Milk: IM vaccination significantly increased IgG and IgA in early mature milk.
  • Secretions: Neither route significantly increased HA-specific IgG/IgA in nasal or oral secretions compared to controls, though IN showed a modest trend in nasal IgA.
• Passive Transfer to Piglets:
  • Piglets from IN and IM dams had significantly higher serum HA-specific IgG and IgA compared to controls.
  • Crucial Distinction: While IM piglets had higher total IgG/IgA concentrations, piglets from IN-vaccinated dams exhibited significantly higher influenza-neutralizing antibody titers than all other groups (including IM piglets).
  • HI Assay: IN dams had significantly higher HI titers than controls/oral groups; piglet HI titers were elevated but not statistically distinct between groups.
• Cellular Immunity:
  • IN Route: Generated significantly higher IFNγ-producing cells in peripheral blood mononuclear cells (PBMCs) and a trend in submandibular lymph nodes, suggesting mucosa-homing T-cell trafficking.
  • IM Route: Generated significantly higher IFNγ-producing cells in the spleen, indicating systemic lymphoid activation.
  • Histology: No significant differences in lymphocyte infiltration (T/B cells/plasma cells) in lung or mammary glands were observed between groups.

5. Significance and Conclusion

• Superiority of Intranasal Delivery: The study concludes that Intranasal (IN) immunization is the superior strategy for maternal influenza vaccination in this model. While IM vaccination generates high antibody quantities, IN vaccination generates antibodies with superior functional quality (higher neutralization and HI titers) that are effectively transferred to neonates.
• Mechanism: The IN route likely induces qualitative differences in antibodies (e.g., epitope targeting, affinity maturation, glycosylation) and promotes mucosa-homing T-cell responses that enhance the functional capacity of the transferred immunity.
• Clinical Implication: IN vaccination with Ad5-vectored platforms could serve as a complementary strategy to current IIVs, potentially overcoming the limitations of direct newborn immunization by leveraging the maternal immune system to provide high-quality, functional passive protection during the vulnerable first six months of life.
• Oral Route Failure: The failure of the oral route highlights the importance of vector-receptor compatibility (Ad5-CAR) in the gut for this specific platform in pigs.